Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2012

View Archived Issues

New claudin-6-binding antibodies patented in Germany

Novel platinum(IV) complexes disclosed by Universidad Autonoma de Madrid

Allergan presents novel agents for ocular disorders

Galderma Pharma prepares new agent for rosacea

New human papillomavirus vaccines developed in China

Novel orexin OX receptor antagonists discovered at Actelion Pharmaceuticals

New mechanism of action reveals potential of salirasib to treat rare lung disorder

Two-gene signature predicts prognosis of previously untreated chronic lymphocytic leukemia

Shire and Sangamo BioSciences enter agreement for hemophilia therapeutics

IDRI contributes to Sabin Vaccine Institute's first-ever hookworm vaccine study

Boehringer Ingelheim selects Nanobody candidate from Ablynx alliance

ThromboGenics plans to resubmit ocriplasmin BLA for priority review

Study identifies new therapeutic target for refractory inflammation in COPD

Impax Pharmaceuticals gains U.S. rights to migraine therapy

FDA advisory committee sets review date for lorcaserin NDA resubmission

U.S. team designs new nanoparticle delivery systems to target chemotherapy to cancer cells

Phase III tuberculosis trial completes enrollment

Eusa Pharma acquires Asparec rights

Phase III lubiprostone study meets primary endpoint

New gene expression signature predicts outcome of patients with basal-like breast cancer

Boston Scientific launches Promus Element Plus stent system in Europe

Navidea Biopharmaceuticals receives CHMP advice on Lymphoseek MAA

Dosing begins in phase II AFN-1252 study in ABSSSI

WHO releases roadmap for work to eliminate neglected tropical diseases

Athersys receives grant to develop stem cell therapy for traumatic brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...